Pharmacokinetic and Pharmacodynamic Study of the Human Immunodeficiency Virus Protease Inhibitor Amprenavir after Multiple Oral Dosing

In a dose-ranging study of amprenavir (formerly 141W94), an inhibitor of the protease enzyme of human immunodeficiency virus (HIV) type 1, single-dose and steady-state pharmacokinetic parameters were estimated from plasma samples collected on day 1 and during week 3, respectively. Amprenavir was adm...

Descripció completa

Dades bibliogràfiques

Publicat a:	Antimicrob Agents Chemother
Autors principals:	Sadler, Brian M., Gillotin, Catherine, Lou, Yu, Stein, Daniel S.
Format:	Artigo
Idioma:	Inglês
Publicat:	American Society for Microbiology (ASM) 2001
Matèries:	Antiviral Agents
Accés en línia:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC90235/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/11120940/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/AAC.45.1.30-37.2001
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!